Cover Image

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Corrado Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Rosa Terracciano,3 Rocco Savino,3 Girolamo Pelaia1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, 2Department...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pelaia C (Author), Vatrella A (Author), Busceti MT (Author), Gallelli L (Author), Terracciano R (Author), Savino R (Author), Pelaia G (Author)
Format:	Book
Published:	Dove Medical Press, 2017-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Role of biologics in severe eosinophilic asthma – focus on reslizumab
by: Pelaia G, et al.
Published: (2016)

Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
by: Girolamo Pelaia, et al.
Published: (2015)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
by: Pelaia C, et al.
Published: (2021)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
by: Pelaia G, et al.
Published: (2015)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
by: Menzella F, et al.
Published: (2016)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
by: Manuel David Gil-Sierra, et al.
Published: (2019)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
by: Olalla Montero-Pérez, et al.
Published: (2019)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
by: Corrado Pelaia, et al.
Published: (2022)

Severe Pediatric Asthma Therapy: Mepolizumab
by: Nicola Ullmann, et al.
Published: (2022)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
by: Carlo Lombardi, et al.
Published: (2024)

Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience
by: Anna Agnese Stanziola, et al.
Published: (2024)

Targeting interleukin-4 and interleukin-13 in the treatment of severe eosinophilic asthma
by: Nightingale Syabbalo
Published: (2023)

A retrospective analysis of severe asthma treatment with Mepolizumab
by: Mattia Serao, et al.
Published: (2019)

Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach
by: Gallelli L, et al.
Published: (2017)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
by: Nina B. Curkovic, MD, et al.
Published: (2024)

Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission
by: B. Cremonezi Lammoglia, et al.
Published: (2023)

MALDI MS-Based Investigations for SARS-CoV-2 Detection
by: Mariaimmacolata Preianò, et al.
Published: (2021)

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance
by: Adam Kisling, et al.
Published: (2020)

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
by: Mattia Giovannini, et al.
Published: (2019)

Use of Mepolizumab in Children and Adolescents with Asthma in the USA
by: Jaclyn Davis, et al.
Published: (2022)

Targeted therapy in severe asthma today: focus on immunoglobulin E
by: Pelaia G, et al.
Published: (2017)

Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings
by: Takaharu Ikeda, et al.
Published: (2023)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
by: Madeleine Lachance, MD, et al.
Published: (2022)

Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation
by: L. H. Faccioli, et al.
Published: (1998)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020)

Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature
by: Marco Maglione, et al.
Published: (2024)

Efficacy of Mepolizumab in the Treatment of Severe Asthma with a Mixed Granulocytic Pattern of Airway Inflammation (Case Report)
by: A. M. Gubareva, et al.
Published: (2024)

Targeting eosinophils: severe asthma and beyond
by: Marco, et al.
Published: (2019)

Novel treatment of severe eosinophilic asthma
by: article editorial
Published: (2020)

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)
by: Mahboub B, et al.
Published: (2022)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
by: Magdalena Żychowska, et al.
Published: (2020)

Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation
by: Florence E. Roufosse
Published: (2018)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
by: Faverio P, et al.
Published: (2018)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017)

Oral Formulation of Angiotensin-(1-7) Promotes Therapeutic Actions in a Model of Eosinophilic and Neutrophilic Asthma
by: Giselle Santos Magalhães, et al.
Published: (2021)

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
by: Christian Domingo, et al.
Published: (2023)

Eosinophils and childhood asthma
by: Bong Seok Choi
Published: (2021)

Interleukin-5 Potentiates Sulfidopeptide Leukotriene Production by Human Eosinophils
by: A. J. M. Van Oosterhout, et al.
Published: (1994)